We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+18.41%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
+$36.6M
Cap. Flow
+$22.8M
Cap. Flow %
13.88%
Top 10 Hldgs %
53.05%
Holding
50
New
5
Increased
29
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.39M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$4.21M
3
LLY icon
Eli Lilly
LLY
+$3.54M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$3.38M
5
OPCH icon
Option Care Health
OPCH
+$3.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$4.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.52M
3
CI icon
Cigna
CI
+$4.49M
4
COR icon
Cencora
COR
+$4.25M
5
GILD icon
Gilead Sciences
GILD
+$3.61M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
26
IQVIA
IQV
$40.1B
$2.54M 1.55%
10,058
-282
-3% -$65.8K
EW icon
27
Edwards Lifesciences
EW
$54B
$2.37M 1.44%
24,775
+3,960
+19% +$333K
SWAV
28
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.55M 0.94%
4,751
+1,221
+35% +$300K
CRBP icon
29
Corbus Pharmaceuticals
CRBP
$184M
$1.49M 0.91%
+38,000
New +$937K
CABA icon
30
Cabaletta Bio
CABA
$455M
$1.32M 0.8%
77,540
+56,540
+269% +$1.21M
ACLX
31
DELISTED
Arcellx
ACLX
$1.22M 0.74%
17,496
+6,096
+53% +$387K
KRYS icon
32
Krystal Biotech
KRYS
$9.68B
$1.18M 0.72%
6,624
– –
BBIO icon
33
BridgeBio Pharma
BBIO
$16.4B
$1.17M 0.71%
37,841
+13,856
+58% +$471K
EXAS
34
DELISTED
Exact Sciences
EXAS
$1.11M 0.68%
16,120
+3,963
+33% +$251K
MRUS
35
DELISTED
Merus
MRUS
$1.1M 0.67%
24,325
– –
INSP icon
36
Inspire Medical Systems
INSP
$1.71B
$1.03M 0.63%
4,782
+1,553
+48% +$304K
CYTK icon
37
Cytokinetics
CYTK
$10.6B
$982K 0.6%
14,000
+2,267
+19% +$175K
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.4B
$945K 0.58%
3,539
+1,008
+40% +$238K
MGNX icon
39
MacroGenics
MGNX
$249M
$726K 0.44%
+49,307
New +$745K
AKRO
40
DELISTED
Akero Therapeutics
AKRO
$617K 0.38%
24,432
+9,000
+58% +$216K
AUTL
41
Autolus Therapeutics
AUTL
$620M
$615K 0.37%
96,345
– –
NAMS icon
42
NewAmsterdam Pharma
NAMS
$3.3B
$530K 0.32%
+22,394
New +$455K
MORF
43
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$526K 0.32%
14,952
– –
MRSN
44
DELISTED
Mersana Therapeutics
MRSN
$448K 0.27%
+4,000
New +$398K
BMY icon
45
Bristol-Myers Squibb
BMY
$130B
– –
-88,000
Closed -$4.52M
CI icon
46
Cigna
CI
$72.4B
– –
-15,000
Closed -$4.49M
CNC icon
47
Centene
CNC
$32.1B
– –
-62,000
Closed -$4.6M
PFE icon
48
Pfizer
PFE
$152B
– –
-42,820
Closed -$1.23M
PRTA icon
49
Prothena Corp
PRTA
$473M
– –
-8,342
Closed -$303K
AMAM
50
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-57,847
Closed -$824K
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

HealthInvest Partners's Q1 2024 Portfolio in Review

As of Q1 2024, HealthInvest Partners held 50 positions worth $164M, up 29% from $128M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

HealthInvest Partners deployed $22.8M of net new capital in Q1 2024, opening 5 new positions and adding to 29 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 123,000 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cencora, an estimated $4.25M trimmed.

  • HealthInvest Partners's largest Q1 2024 buy was Mirum Pharmaceuticals: 123,000 shares worth $3.09M.
  • HealthInvest Partners added most to Merck in Q1 2024, an estimated $8.39M increase.
  • HealthInvest Partners's biggest Q1 2024 reduction was Cencora, cutting an estimated $4.25M.
  • HealthInvest Partners fully exited Centene in Q1 2024, selling an estimated $4.6M.
  • HealthInvest Partners's ten largest holdings make up 53% of its $164M portfolio in Q1 2024.
  • HealthInvest Partners opened 5 new positions and closed 6 in Q1 2024.
  • HealthInvest Partners's portfolio value rose 29% quarter-over-quarter to $164M.

Based on HealthInvest Partners's 13F filing for Q1 2024, filed 25 Apr 2024.